XOMA Royalty Corporation Common Stock (XOMA) Stock Price

XOMAStock

$0.00−38.70%52W

Market Cap—

P/E22.39x

PEG Ratio2.39

Div yield—

Beta-0.77

XOMA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)41.97%

Price vs S&P 500 (4W)-4.88%

PEG Ratio2.39

VGM Score48.92

P/E Ratio (Annual)22.39x

P/CF (Annual)247.35x

Book Value / Share (Quarterly)$9.48

P/TBV (Annual)5.56x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)105.26%

Cash Flow / Share (Quarterly)$0.57

Payout Ratio (TTM)16.35%

Price vs S&P 500 (YTD)41.21%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)69.63%

EPS (TTM)$2.00

10-Day Avg Trading Volume0.88M

EPS Excl Extra (TTM)$2.00

Revenue Growth (5Y)12.15%

EPS (Annual)$1.76

Dividend / Share (Annual)$0.46

ROI (Annual)14.89%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-217.61%

Cash / Share (Quarterly)$7.23

P/E Basic Excl Extra (TTM)21.00x

Revenue Growth QoQ (YoY)-22.59%

EPS Growth (5Y)8.80%

P/E Normalized (Annual)22.39x

ROA (Last FY)11.63%

Revenue Growth TTM (YoY)13.16%

EBITD / Share (TTM)$2.01

ROE (5Y Avg)-7.01%

Operating Margin (TTM)61.26%

Cash Flow / Share (Annual)$0.24

P/B Ratio6.29x

P/B Ratio (Quarterly)3.31x

Net Income / Employee (Annual)$2,265,100

EV / Revenue (TTM)14.98x

Net Interest Coverage (TTM)6.48x

ROA (TTM)13.12%

EPS Growth QoQ (YoY)182.04%

EV / EBITDA (TTM)22.01x

EPS Incl Extra (Annual)$1.76

Current Ratio (Annual)3.37x

Quick Ratio (Quarterly)3.58x

3-Month Avg Trading Volume0.27M

52-Week Price Return-38.70%

EV / Free Cash Flow (Annual)253.36x

P/E Incl Extra (TTM)21.00x

Revenue / Employee (TTM)$3,468,200

Tangible BV / Share (Quarterly)$5.80

P/S Ratio (Annual)13.62x

Asset Turnover (Annual)0.19x

52-Week High$45.22

Operating Margin (5Y Avg)-226.62%

EPS Excl Extra (Annual)$1.76

Tangible BV CAGR (5Y)79.85%

26-Week Price Return50.90%

Quick Ratio (Annual)3.34x

13-Week Price Return9.28%

Total Debt / Equity (Annual)1.05x

Current Ratio (Quarterly)3.59x

Enterprise Value$727.39M

Revenue / Share Growth (5Y)2.56%

Asset Turnover (TTM)0.19x

Book Value / Share Growth (5Y)2.59%

Revenue / Employee (Annual)$3,724,900

Inventory Turnover (Annual)0.00x

Pretax Margin (Annual)61.01%

Cash / Share (Annual)$7.02

3-Month Return Std Dev35.47%

Gross Margin (5Y Avg)75.37%

Net Income / Employee (TTM)$2,415,000

EBITDA CAGR (5Y)23.38%

EBITDA Interim CAGR (5Y)-15.39%

ROE (Last FY)30.50%

Net Interest Coverage (Annual)3.92x

EPS Basic Excl Extra (Annual)$1.76

P/FCF (TTM)56.40x

Receivables Turnover (TTM)9.58x

EV / Free Cash Flow (TTM)107.06x

Total Debt / Equity (Quarterly)0.91x

EPS Incl Extra (TTM)$2.00

Receivables Turnover (Annual)15.49x

ROI (TTM)15.88%

P/S Ratio (TTM)14.63x

Pretax Margin (5Y Avg)-221.56%

Revenue / Share (Annual)$2.90

Tangible BV / Share (Annual)$4.99

Forward P/E96.55x

Free OCF CAGR (5Y)-22.21%

Price vs S&P 500 (52W)-45.86%

P/E Ratio (TTM)21.00x

Year-to-Date Return51.07%

5-Day Price Return-8.48%

EPS Normalized (Annual)$1.76

ROA (5Y Avg)-2.95%

Net Profit Margin (Annual)60.81%

Month-to-Date Return-5.48%

Cash Flow / Share (TTM)$-2.74

EBITD / Share (Annual)$1.98

Operating Margin (Annual)62.53%

LT Debt / Equity (Annual)0.93x

P/CF (TTM)104.53x

ROI (5Y Avg)-2.77%

P/E Excl Extra (TTM)21.00x

LT Debt / Equity (Quarterly)0.79x

EPS Basic Excl Extra (TTM)$2.00

P/TBV (Quarterly)5.41x

Payout Ratio (Annual)17.26%

P/B Ratio (Annual)3.17x

Dividend / Share (TTM)$0.46

Inventory Turnover (TTM)0.00x

Pretax Margin (TTM)69.85%

Book Value / Share (Annual)$8.77

Price vs S&P 500 (13W)-0.91%

Net Margin Growth (5Y)6.09%

Dividend Yield (TTM)0.78%

Beta-0.77x

P/FCF (Annual)247.35x

Revenue / Share (TTM)$4.08

ROE (TTM)32.41%

52-Week Low$22.29

vGradeD

gGradeC

mGradeB

vgmGradeC

XOMA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q4 2025	Mar 18, 2026	-$0.13	$0.26	+300.00%(+$0.39)
Q3 2025	Nov 12, 2025	-$0.04	$0.70	+1850.00%(+$0.74)
Q2 2025	Aug 13, 2025	-$0.15	$0.44	+393.33%(+$0.59)

XOMA Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.89

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
XOMAXOMA Royalty Corporation Common Stock	D	C	B	14.6x	13.2%	100.0%	8.8%	$0.00
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About XOMA Royalty Corporation Common Stock

XOMA Royalty Corp acquires future revenue rights from pre-commercial drug candidates licensed to pharmaceutical and biotechnology companies. This non-dilutive funding model enables biotech firms to advance their internal drug development without equity dilution. The company operates globally across the United States, Europe, Asia Pacific, and Switzerland.